CEBPB and Hepatic fibrosis: Therefore, C/EBPβ+/+ mice with severe liver fibrosis, after receiving CCl4 for 8 weeks, were treated with the RSK inhibitory peptide for an additional 4 or 8 weeks (5 μg IP, three times/week, for week 9, followed by 1 μg IP, three times/week for weeks 10–12 or 10–16), while continuing to induce liver injury and fibrosis with CCl4.